<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105464</url>
  </required_header>
  <id_info>
    <org_study_id>SYHA1815-202001/PRO</org_study_id>
    <nct_id>NCT05105464</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Multi-center, Open-label, Dose Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) Characteristic of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Runshi Pharmaceutical Technology Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jilin Provincial Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Runshi Pharmaceutical Technology Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, dose escalation and expansion, phase I study to&#xD;
      investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD)&#xD;
      characteristics, preliminary efficacy of SYHA1815 in subjects with unresectable locally&#xD;
      advanced or metastatic solid tumors. Once the expected effective dose is identified, the dose&#xD;
      expansion study will be started to further evaluate the safety, clinical activity and PK&#xD;
      profile of SYHA1815 in subjects with unresectable locally advanced or metastatic solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, dose escalation and expansion, phase I study to&#xD;
      investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD)&#xD;
      characteristics, preliminary efficacy of SYHA1815 in subjects with unresectable locally&#xD;
      advanced or metastatic solid tumors. The dose escalation study will include six dose cohorts&#xD;
      starting at 2 mg/day. Once the expected effective dose is identified, the dose expansion&#xD;
      study will be started to further evaluate the safety, clinical activity and PK profile of&#xD;
      SYHA1815 in subjects with unresectable locally advanced or metastatic solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose-limiting Toxicities</measure>
    <time_frame>Baseline through 28 days after the first dose of study drug</time_frame>
    <description>Number of participants with Dose-limiting Toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events and SAEs</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Incidence of adverse events and SAEs defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes from baseline in routine blood test</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Clinically significant changes from baseline in routine blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes from baseline in blood biochemistry test</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Clinically significant changes from baseline in blood biochemistry test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes from baseline in routine urine test</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Clinically significant changes from baseline in routine urine test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes from baseline in coagulation function test</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Clinically significant changes from baseline in coagulation function test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes from baseline in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Clinically significant changes from baseline in 12-lead electrocardiogram (ECG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes from baseline in vital signs examination</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Clinically significant changes from baseline in vital signs examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes from baseline in physical examination</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Clinically significant changes from baseline in physical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Assessed by Blinded Independent Review Committee (IRC) per RECIST Version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Disease control rate (DCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Progression free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time to maximum plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Maximum Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T1/2)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Plasma half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to time t (AUC0-t)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time t (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to infinity (AUCinf)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to infinity (AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal disposition rate constant (λz)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Terminal disposition rate constant (λz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total clearance of the drug from plasma after oral administration (CL/F)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Apparent total clearance of the drug from plasma after oral administration (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during terminal phase after non-intravenous administration (Vz/F)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Apparent volume of distribution during terminal phase after non-intravenous administration (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum phosphate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Change from baseline in serum phosphate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum carcinoembryonic antigen (CEA)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Serum carcinoembryonic antigen (CEA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcitonin (thyroid cancer detection only)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Calcitonin (thyroid cancer detection only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroblast growth factor 23 (FGF23)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Fibroblast growth factor 23 (FGF23)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular endothelial growth factor receptor 2 (sVEGFR2)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Vascular endothelial growth factor receptor 2 (sVEGFR2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential population who benefit from the study drug</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>To evaluate the efficacy of the study drug in patients with different indications according to the results of anti-tumor response rate in the corresponding indications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the changes of RET/FGFR gene and efficacy</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The percentage of patients with RET/FGFR gene in patients who benefit from the study drug will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Locally Advanced Unresectable Carcinoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six dose levels will be tested. The dose-limiting toxicity (DLT) will be assessed from the first administration of SYHA1815 to the end of the first cycle (28 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the expected effective dose is determined, four expansion cohorts will be started to further evaluate the safety, clinical activity and PK profile of SYHA1815.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYHA1815</intervention_name>
    <description>Subjects will receive SYHA1815 orally.</description>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <arm_group_label>cohort Expansion Cohort</arm_group_label>
    <other_name>SYHA1815 tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects aged 18 to 75 years (inclusive)；&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of unresectable locally advanced&#xD;
             or metastatic solid tumors (thyroid cancer, non-small cell lung cancer, gastric cancer&#xD;
             [including gastroesophageal junction cancer], colorectal cancer, pancreatic cancer,&#xD;
             soft tissue sarcoma, etc.), failure of standard treatment (disease progression or&#xD;
             intolerance), or no alternative standard treatment or refusal of standard treatment;&#xD;
&#xD;
          -  The subjects included in the dose expansion study should provide written biomarker&#xD;
             test reports or tumor tissue samples to the central laboratory;&#xD;
&#xD;
          -  The time interval between the last dose of anti-tumor drug and the first&#xD;
             administration of SHYA1815 must meet the following conditions: ≥ 4 weeks for cytotoxic&#xD;
             drugs, PD-1 / PD-L1, cellular immunotherapy; ≥2 weeks for oral molecular targeted drug&#xD;
             therapy; ≥4 weeks for radiotherapy (≥ 2 weeks for palliative local radiotherapy for&#xD;
             pain relief), and had recovered from the toxicities of radiotherapy; ≥2 weeks for&#xD;
             anticancer Traditional Chinese medicine or Chinese patent medicine;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks;&#xD;
&#xD;
          -  At least one measurable lesion according to RECIST 1.1 at the screening phase;&#xD;
&#xD;
          -  The organ function level and related laboratory values of the subjects must meet the&#xD;
             following requirements within 7 days before the first dose of study drug (not&#xD;
             receiving blood transfusion within 14 days before the first administration):&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L; Platelet count ≥ 75 × 10^9/L /L;&#xD;
                  Hemoglobin ≥ 90 g / L; the values of blood phosphorus and calcium are in normal&#xD;
                  range;&#xD;
&#xD;
               2. Blood biochemistry: serum total bilirubin ≤ 1.5× upper limit of normal value&#xD;
                  (ULN); AST / ALT ≤ 3 ×ULN (≤ 5 ×ULN for liver metastasis); Serum creatinine ≤ 1.5&#xD;
                  × ULN;&#xD;
&#xD;
               3. Coagulation: Internationally standardized ratio (INR) or prothrombin time (PT) ≤&#xD;
                  1.5×ULN, activated partial thrombin time (APTT) ≤ 1.5×ULN;&#xD;
&#xD;
          -  For women of childbearing potential: the serum pregnancy test within 7 days before the&#xD;
             first administration must be negative, and female subjects are willing to take&#xD;
             adequate contraceptive measures during the treatment period and for at least 3 months&#xD;
             after the last dose of the study drug. Male subjects must agree to take contraceptive&#xD;
             measures (non-drug or instrumental contraception) from the beginning of the study to&#xD;
             at least 3 months after the last dose of study drug;&#xD;
&#xD;
          -  Voluntarily participate in the study and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The previous anti-tumor or surgical treatment history with any of the following&#xD;
             conditions:&#xD;
&#xD;
               1. Received the treatment of other intervention clinical studies with 4 weeks before&#xD;
                  the first dose of study drug;&#xD;
&#xD;
               2. Had undergone major surgery within 4 weeks before the first dose of study drug or&#xD;
                  had not fully recovered from any previous invasive operation;&#xD;
&#xD;
               3. Prior treatment of RET/FGFR inhibitors or small molecular kinase inhibitors with&#xD;
                  RET/FGFR as the main targets;&#xD;
&#xD;
          -  Any unresolved toxicities from prior anti-tumor therapy greater than Common&#xD;
             Terminology Criteria for Adverse Events (CTCAE) Grade 1, except for alopecia,&#xD;
             pigmentation, previous chemotherapy-related neurotoxicity (≤ grade 2) and other&#xD;
             adverse reactions judged no safety risk by the investigators;&#xD;
&#xD;
          -  Subjects with symptomatic brain metastasis or meningeal metastasis, spinal cord&#xD;
             compression or mental disorder, and asymptomatic brain metastasis can be enrolled&#xD;
             (there is no disease progress within at least 4 weeks after radiotherapy and/or no&#xD;
             neurological symptoms after surgical resection, and glucocorticoids, anticonvulsant&#xD;
             drugs and mannitol are not required);&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiovascular and cerebrovascular&#xD;
             diseases, including any of the following:&#xD;
&#xD;
               1. History of myocardial infarction, congestive heart failure (NYHA grade ≥ grade&#xD;
                  III), and unstable angina pectoris within 6 months prior to screening;&#xD;
&#xD;
               2. Cerebrovascular disease occurred within 6 months before screening (except for&#xD;
                  transient ischemic attack (TIA), lacunar infarction with no clinical&#xD;
                  significance);&#xD;
&#xD;
               3. Severe uncontrollable arrhythmia requiring medical treatment;&#xD;
&#xD;
               4. Electrocardiogram (ECG) examination, female QTc interval&gt;470 milliseconds (ms),&#xD;
                  male QTc interval&gt;450 milliseconds (ms) according to Fridericia formula;&#xD;
&#xD;
               5. The left ventricular ejection fraction is less than 50% according to cardiac&#xD;
                  ultrasound examination;&#xD;
&#xD;
          -  History of active bleeding within 6 months before screening;&#xD;
&#xD;
          -  Any serious or uncontrollable disease, and not suitable for this study as determined&#xD;
             by the investigator;&#xD;
&#xD;
          -  Any uncontrollable active infection that will prevent the subjects from receiving the&#xD;
             study drug within 2 weeks prior to the first dose of study drug;&#xD;
&#xD;
          -  HIV positive, HCV positive with HCV RNA quantity higher than the upper limit of normal&#xD;
             value in the research center;&#xD;
&#xD;
          -  Active hepatitis B infection, with the HBV DNA quantity higher than the upper limit of&#xD;
             normal value of the research center;&#xD;
&#xD;
          -  A history of any other malignant tumors within 5 years (except for effectively&#xD;
             controlled non-melanoma skin basal cell carcinoma, cervical carcinoma in situ, and&#xD;
             other malignant tumors that have been effectively controlled without treatment in the&#xD;
             past 5 years;&#xD;
&#xD;
          -  Subjects who have taken potent inhibitors and inducers of CYP3A4 liver metabolic&#xD;
             enzymes within 2 weeks before the first administration and still need to continue to&#xD;
             use such drugs;&#xD;
&#xD;
          -  Women who are breastfeeding;&#xD;
&#xD;
          -  Concomitant disease or condition that may interfere with the conduct of the trial, or&#xD;
             that would pose an unacceptable risk to the subject in this trial in the opinion of&#xD;
             the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huang Yanli, PD</last_name>
    <role>Study Director</role>
    <affiliation>CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Li, AM</last_name>
    <phone>13321898532</phone>
    <email>lcliyang@mail.ecspc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Ying, doctor</last_name>
      <phone>0431-85873390</phone>
      <email>jl.cheng@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced unresectable or metastatic solid tumors</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

